This article is part of Ophthalmology Advisor’s Focus on Retina coverage from the 2021 meeting of the American Academy of Ophthalmology, held in New Orleans from November 12 to 15, 2021. The team at Ophthalmology Advisor will be reporting on a variety of the research presented by the retinal experts at the AAO. Check back for more from the AAO 2021 Meeting.
Patients with noninfectious retinal vasculitis who received infliximab or tocilizumab infusions showed comparable improvements in outcomes, according to research presented at the American Academy of Ophthalmology 2021 annual meeting, held in New Orleans from November 12-15.
The group that received infliximab (5-10 mg/kg) consisted of 24 eyes from 14 patients. The second group received tocilizumab infusions (4-8 mg/kg) and consisted of 11 eyes from 8 patients. Researchers evaluated all patients at baseline as well as after 6 months. Visual acuity (VA), anterior chamber cell and flare, vitreous haze, central subfield thickness (CST), and fluorescein angiography (FA) scoring, using the Angiographic Scoring for the Uveitis Working Group, were assessed.
The mean improvements in VA (logMAR) and CST (microns) were 0.04±0.14 and 40.3±78.5 in the infliximab group and 0.04±0.09 and 47.3±82.3 in patients receiving tocilizumab, respectively. The 2 groups showed similar reductions in mean FA scores from baseline to 6-month follow-up. Mean FA scores in patients receiving infliximab dropped from 12.4±5.2 at baseline to 6.4±5.0 at 6 months, and the average FA score for the tocilizumab group was reduced from 11.6±4.4 to 5.8±3.9.
The researchers noted no statistically significant differences between the 2 treatments in improvement of mean FA scores (P =.929).
Karaca, I, Uludag G, Ghoraba H, et al. Comparison of efficacy of infliximab and tocilizumab in noninfectious retinal vasculitis: six-month outcomes. Paper presented at: The American Academy of Ophthalmology 2021 Annual Meeting; November 12-15, 2021; New Orleans. Abstract PA008.